Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Deuschl G, Oertel W, Reichmann H. Idiopathisches Parkinson-Syndrom. Leitlinie Entwicklungsstufe S3, Aktualisierung 2016, AWMF-Register-Nr. 030-010. Deutsche Gesellschaft für Neurologie (Hrsg.) 2016;
www.dgn.org
2. Deleu D, Hanssens Y, Northway MG. Subcutaneus apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs Aging 2004; 21: 687–709
3. LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004; 62: S8–S11
4. Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, et al. Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease — clinical practice recommendations. Park Rel Disord 2015; 21:1023–30
5. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156–63